Berenberg keeps Hold for Evotec stock at EUR 3.60 target

Published on 10/08/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 16.20 percent to EUR 143.48 million in the second quarter. Evotec stock costs EUR 2.88 on October 8, 2026 versus EUR 2.91.

Isometrische 3D-Illustration einer Wirkstoffforschungs-Wertschöpfungskette mit Molekülen und Laborrobotern — Isometrische 3D-Grafik zeigt den Wirkstoffscreening-Prozess der Biotech-Branche von Evotec SE, ISIN DE0005664809, als Wertschöpfungskette, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) had a EUR 3.60 price target and a Hold rating from Berenberg on September 24, 2026, according to FinanzNachrichten. Evotec stock was trading at EUR 2.88 at Lang & Schwarz on October 8, 2026 at 1:33 p.m. CEST, down 1.03 percent versus the EUR 2.91 prior close.

Why Berenberg kept Hold

Berenberg analyst Christian Ehmann said the company's scientific strength was being overshadowed by commercial restructuring and delayed milestones, according to the September 24, 2026 study carried by FinanzNachrichten. The EUR 3.60 target lies 25.00 percent above the Lang & Schwarz price of EUR 2.88, a gap that reflects both recovery potential and execution risk.

Three milestones shaped the reset

On September 2, 2026, Evotec agreed a research cooperation with Plectonic Biotech involving its BiTco platform and T-cell therapies, as reported by Stock-World. On September 9, 2026, its Just-Evotec Biologics unit advanced the JST-018 antibody program into a Phase I study against orthopoxviruses, according to Boerse Express. Berenberg's September 24 assessment was the latest dated external milestone in this sequence.

What does the target imply?

The operating numbers explain why the target is conditional rather than a forecast. Revenue fell 16.20 percent year over year to EUR 143.48 million in the second quarter of 2026 from EUR 171.24 million, while adjusted EBITDA was a loss of EUR 20.80 million, according to Boerse Express. For the first half of 2026, revenue reached EUR 300.10 million and adjusted EBITDA was minus EUR 42.70 million, leaving cost execution and partnership income as the key operational tests.

Next reporting date is November 5

Evotec's next quarterly results were listed for November 5, 2026 by Stock-World. The date will provide the next quantified test of revenue conversion and the Horizon restructuring program.

Evotec stock stays under pressure

At Lang & Schwarz, Evotec was trading at EUR 2.88 on October 8, 2026 at 1:33 p.m. CEST, minus 1.03 percent versus the EUR 2.91 prior close. On Xetra, the stock is classified in biotechnology and the TecDAX, according to the master-data information published by FinanzNachrichten. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.